Literature DB >> 27130375

Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice.

Marie-Lorraine Chrétien1, Caroline Legouge1, Romain Z Martin2, Arlette Hammann3, Malika Trad4, Romain Aucagne2, Anne Largeot2, Jean-Noël Bastie1, Laurent Delva5, Ronan Quéré2.   

Abstract

Trim33/Tif1γ (Trim33) is a member of the tripartite motif family. Using a conditional hematopoietic-specific Trim33 knock-out (Trim33(Δ/Δ)) mouse, we showed previously that Trim33 deficiency in hematopoietic stem cells leads to severe defects in hematopoiesis, resembling the main features of human chronic myelomonocytic leukemia. We also demonstrated that Trim33 is involved in hematopoietic aging through TGFβ signaling. Nevertheless, how Trim33 contributes to the terminal stages of myeloid differentiation remains to be clarified. We reveal here the crucial role of Trim33 expression in the control of mature granulomonocytic differentiation. An important component of Trim33-deficient mice is the alteration of myeloid differentiation, as characterized by dysplastic features, abnormal granulocyte and monocyte maturation, and the expansion of CD11b(+)Ly6G(high)Ly6C(low) myeloid cells, which share some features with polymorphonuclear-myeloid-derived suppressor cells. Moreover, in Trim33(Δ/Δ) mice, we observed the alteration of CSF-1-mediated macrophage differentiation in association with the lack of Csf-1 receptor. Altogether, these results indicate that Trim33 deficiency leads to the expansion of a subset of myeloid cells characterizing the myelodysplastic/myeloproliferative neoplasm.
Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27130375     DOI: 10.1016/j.exphem.2016.04.009

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

Review 1.  Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer.

Authors:  Audrey Aussy; Olivier Boyer; Nadège Cordel
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

2.  Macrophage production and activation are dependent on TRIM33.

Authors:  Anne-Sophie Gallouet; Federica Ferri; Vanessa Petit; Aude Parcelier; Daniel Lewandowski; Nathalie Gault; Vilma Barroca; Stéphanie Le Gras; Eric Soler; Frank Grosveld; Irwin Davidson; Paul-Henri Romeo
Journal:  Oncotarget       Date:  2017-01-17

Review 3.  The Roles of TIF1γ in Cancer.

Authors:  Chengpeng Yu; Zeyang Ding; Huifang Liang; Bixiang Zhang; Xiaoping Chen
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

4.  TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammation.

Authors:  Vanessa Petit; Aude Parcelier; Cecile Mathé; Vilma Barroca; Claire Torres; Daniel Lewandowski; Federica Ferri; Anne-Sophie Gallouët; Marion Dalloz; Océane Dinet; Gilles Boschetti; Marie-Catherine Vozenin; Paul-Henri Roméo
Journal:  EBioMedicine       Date:  2019-05-24       Impact factor: 8.143

5.  TRIM33 protects osteoblasts from oxidative stress-induced apoptosis in osteoporosis by inhibiting FOXO3a ubiquitylation and degradation.

Authors:  De-Bo Zou; Zongyou Mou; Wenliang Wu; Haichun Liu
Journal:  Aging Cell       Date:  2021-06-08       Impact factor: 9.304

6.  Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.

Authors:  Shuhei Asada; Susumu Goyama; Daichi Inoue; Shiori Shikata; Reina Takeda; Tsuyoshi Fukushima; Taishi Yonezawa; Takeshi Fujino; Yasutaka Hayashi; Kimihito Cojin Kawabata; Tomofusa Fukuyama; Yosuke Tanaka; Akihiko Yokoyama; Satoshi Yamazaki; Hiroko Kozuka-Hata; Masaaki Oyama; Shinya Kojima; Masahito Kawazu; Hiroyuki Mano; Toshio Kitamura
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

Review 7.  Ubiquitin Ligases Involved in the Regulation of Wnt, TGF-β, and Notch Signaling Pathways and Their Roles in Mouse Development and Homeostasis.

Authors:  Nikol Baloghova; Tomas Lidak; Lukas Cermak
Journal:  Genes (Basel)       Date:  2019-10-16       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.